Researchers from Curtin University in Australia have advanced research against Alzheimer’s disease by designating a probable cause of this alteration which would affect, for France, nearly a million people.
Wednesday, September 15, 2021 in the scientific journal PLOS Biology, researchers at Curtin University have given a detailed verdict of their experiment conducted on mouse models (bats). According to this study, relayed in France through Yahoo, Alzheimer’s disease, The most widespread form of dementia in the world, is thought to be caused by the leakage of fat-carrying particles carrying proteins in the blood which then irrigates the brain. Professor John Mamo, principal investigator of the Curtin Health Innovation Research Institute (CHIRI), indicated in his findings that before this major discovery “We knew that the main characteristic of people living with Alzheimer’s disease was the gradual build-up of toxic protein deposits in the brain called beta-amyloid but we didn’t know where the amyloid came from or why it got deposited in the brain“.
With pride, the one who led a collective of scientists explained: “Our research shows that these toxic protein deposits that form in the brains of people with Alzheimer’s disease most likely infiltrate the brain from particles that carry fat in the blood, called lipoproteins.“What they call the”blood-brain pathway“opens the field of possibilities for a whole new treatment which would aim to control the blood levels of lipoproteins-amyloid, but also to stem their potential leakage in the brain.
Slowdown in Alzheimer’s disease, soon a reality?
Read also: The first village for Alzheimer’s patients welcomes its inhabitants.
“As we predicted, the study found that mouse models producing lipoprotein-amyloid in the liver suffered from inflammation in the brain, accelerated brain cell death, and memory loss. This finding shows that the abundance of these toxic protein deposits in the blood could potentially be addressed through a person’s diet and certain drugs could specifically target amyloid lipoproteins, thereby reducing their risk or slowing the progression of the disease. ‘Alzheimer’s“, concluded Professor John Mamo. Far from stopping on this observation, the team is actively engaged in clinical trials.